{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:32:30Z","timestamp":1740115950587,"version":"3.37.3"},"reference-count":5,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.2337\/dci24-0080","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:02:01Z","timestamp":1740081721000},"page":"e32-e32","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653\u2013659"],"prefix":"10.2337","volume":"48","author":[{"given":"Maria C.","family":"Foss-Freitas","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7716","authenticated-orcid":false,"given":"David T.","family":"Broome","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-1144","authenticated-orcid":false,"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025022020015932400_B1","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.2337\/dc24-1777","article-title":"Comment on Foss-Freitas et\u00a0al. Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy. Diabetes Care 2024;47:653\u2013659 (Letter)","volume":"48","author":"Zhou","year":"2025","journal-title":"Diabetes Care"},{"key":"2025022020015932400_B2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"},{"key":"2025022020015932400_B3","doi-asserted-by":"crossref","first-page":"1417613","DOI":"10.3389\/fgene.2024.1417613","article-title":"Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Genet"},{"key":"2025022020015932400_B4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ajmg.a.37880","article-title":"Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy","volume":"173","author":"Zolotov","year":"2017","journal-title":"Am J Med Genet A"},{"key":"2025022020015932400_B5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-20-1013","article-title":"LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells","volume":"184","author":"Sollier","year":"2021","journal-title":"Eur J Endocrinol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/3\/e32\/800090\/dci240080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/3\/e32\/800090\/dci240080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:02:03Z","timestamp":1740081723000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/3\/e32\/157911\/Response-to-Comment-on-Foss-Freitas-et-al-Efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci24-0080","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}